Braveheart Bio Hosts Investor Webinar on Cardiac Myosin Inhibitor Program

PUBT · 2d ago
Braveheart Bio Hosts Investor Webinar on Cardiac Myosin Inhibitor Program
  • Braveheart Bio will host an investor and analyst webinar Nov. 6, 2026, from 4:35 p.m. to 6:05 p.m. ET.
  • Presentations will focus on cardiac myosin inhibitor BHB-1893’s global clinical development in obstructive and non-obstructive hypertrophic cardiomyopathy.
  • Management will be joined by physicians Anjali Owens and Mariko Harper, with a live question-and-answer session following presentations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Braveheart Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300730PRIMZONEFULLFEED9856735) on October 30, 2026, and is solely responsible for the information contained therein.